Trump expects voters to fall for the same health care trick twice

As a presidential candidate four years ago, Donald Trump not only railed against the Affordable Care Act; he also made bold promises about the magnificence of his alternative plan. The Republican’s alternative to “Obamacare” would offer everything Americans they could dream of, including better coverage at a lower price. All voters had to do was elect him.

In reality, of course, Trump didn’t know and didn’t care about how to deliver on these promises. He was peddling post-policy nonsense, counting on the electorate to not know the difference.

As a president, when it came time to follow through, Trump was lost without a map, amazed to discover the complexities of an issue he never he even tried to understand. The Republican endorsed plans that did the opposite of what he told voters he’d do, and when it came time to engage in actual negotiations, Trump struggled to keep up —

Read More

BioNTech expects pre-reserved vaccine bottling capacity to be freed up

By Ludwig Burger

FRANKFURT (Reuters) – BioNTech said global capacity to bottle new COVID-19 vaccines, which is in tight supply as producers hoping to develop successful candidates book up slots, will likely be more freely available once some drop out of the race.

“If clinical trials fail or get delayed, capacity may be freed up again,” Sierk Poetting, BioNTech’s head of operations and finance, told an online news conference on Thursday.

“The (fill and finish) market is indeed very tight because everyone has reserved capacity, but I believe we will see some adjustments there once the first products are on the market,” he said.

“This is certainly a type of capacity that can be more easily transferred (than production capacity).”

More than 40 experimental vaccines are currently being tested on volunteers around the globe to combat the new coronavirus, which has claimed more than 1 million lives.

Also speaking at

Read More

Dr. Anthony Fauci backs universal health care, expects slow return to ‘normal’

Dr. Anthony Fauci joined the Berkeley Forum on Thursday, Oct. 8,for a discussion about COVID-19 in the U.S. (Berkeley Forum video)

Observing just five simple public health measures — wearing face masks in public, keeping a physical distance of at least 6 feet, avoiding crowds, engaging in activities outdoors rather than indoors, and washing hands frequently — could significantly blunt the spikes in COVID-19 cases that continue to pop up throughout the U.S.

That’s according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and a current member of the White House Coronavirus Task Force, who spoke at a live virtual Berkeley Forum event on Thursday (Oct. 8).

The event drew nearly 3,500 live viewers to the Forum’s Facebook and YouTube livestreams — enough to fill UC Berkeley’s Zellerbach Hall, The Playhouse and Wheeler Hall combined — said Kaho Otake, a third-year UC Berkeley

Read More

Department of Health expects 1 million doses of COVID-19 antibody treatments by end of 2020

A government official said on Friday that he expects two leading drug manufacturers to produce 1 million doses of antibody treatments to be administered to the public at no cost.

© Provided by Washington Examiner

Department of Health and Human Services official Paul Mango told reporters that the government’s Operation Warp Speed program already has produced “a couple of hundred thousand doses” of the treatments so far.

Mango said the department expects 1 million doses of the antibody treatments to be produced by Regeneron Pharmaceuticals and Eli Lilly & Company by the end of 2020. Mango reiterated President Trump, who said earlier this week that the drugs would be given to patients who need them for free.

Both Regeneron and Eli Lilly have insisted that their treatments, which differ in their administration, have been shown to be safe during clinical trials. Regeneron’s drug relies on a mix of two

Read More

Fruit d’Or Expects Big Impact of Qualified Health Claim for Cranberry Supplements

Silver Spring, MD—FDA has authorized a qualified health claim for supplements containing a daily serving of 500mg of whole fruit cranberry, according to a press release from Fruit d’Or.

The press release explains that three wording options have been authorized, including: “Limited scientific evidence shows that by consuming 500 mg each day of cranberry dietary supplement, healthy women who have had a urinary tract infection (UTI) may reduce their risk of recurrent UTI.”

“Fruit d’Or, a farm-to-finish company, is one of the primary beneficiaries of this great news. More companies are calling us looking to formulate with whole fruit cranberry powder because no one else has our level of expertise,” said Jean Leclerc, Director of Sales and Business Development for Fruit d’Or, in the press release. “With this ruling, the FDA is raising the bar by recognizing whole fruit powder for both its soluble and insoluble proanthocyanins (PACs). We’ve

Read More

Chinese state-backed firm expects coronavirus vaccine approval for public use within months

BEIJING (Reuters) – State-backed vaccine maker China National Biotec Group (CNBG) is hopeful of two of its novel coronavirus vaccine candidates receiving conditional regulatory approval for general public use within the year, its vice president said on Tuesday.

China has inoculated hundreds of thousands of people under an emergency programme authorised in July for essential workers and other limited groups of people considered at high risk of infection, to stave off a resurgence of the coronavirus, even as clinical trials of vaccines are still underway to prove their efficacy and safety.

Inoculating the general public with a workable vaccine is likely to be an important tool in curbing a virus that has led to over 960,000 deaths worldwide. However, expanding vaccine use prior to obtaining long-term data risks raising expert concern.

“CNBG is discussing with relevant state authorities about the requirements for conditional approvals of the two coronavirus vaccines,” Zhang

Read More